Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Idorsia
Biotech
Neurocrine, Idorsia part ways 2 years after double phase 2 fails
Two years after Idorsia and Neurocrine’s calcium channel blocker flunked a pair of phase 2 studies, the biotechs have finally decided to part ways.
James Waldron
Oct 29, 2024 7:15am
Idorsia bags $350M upfront from Viatris for 2 late-phase assets
Feb 28, 2024 7:56am
Idorsia lays off 300 staff after previewing cost cuts in July
Oct 24, 2023 10:30am
J&J hands back $230M blood pressure drug with approval in sight
Sep 6, 2023 6:20am
500 roles threatened as Idorsia tries to reduce cash burn by 50%
Jul 21, 2023 5:13am
Neurocrine axes essential tremor program on phase 2 data
Aug 5, 2022 4:53am
